|Ulcerative colitis (UC) is the most common inflammatory bowel disease worldwide, affecting approximately 600,000 Americans. It is associated with significant morbidity and reduced quality of life. Outcomes in patients with UC are adversely affected by multiple factors, including inadequate treatment. As the therapeutic landscape for this disease continues to evolve, it is critical for physicians to be aware of the most recently approved therapies and emerging agents. In this CME activity, leading experts will discuss the mechanisms of action, safety, and efficacy of available and emerging therapies for UC, as well as their clinical utility.